Management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day highly or moderately emetogenic chemotherapy: role of transdermal granisetron

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Hesketh PJ, Bohlke K, Lyman GH et al. Antiemetics: American Society of Clinical Oncology focused guideline update. J. Clin. Oncol. 34(4), 381–386 (2016). • This is the latest update of the American Society of Clinical Oncology guidelines on antiemetics.
  MedlineGoogle Scholar
• 2 Kris MG, Tonato M, Bria E et al. Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 19(Suppl. 1), S25–S32 (2011).
  MedlineGoogle Scholar
• 3 Graybiel A. Coping with space motion sickness in Spacelab missions. Acta Astronaut. 8(9–10), 1015–1018 (1981).
  Medline CASGoogle Scholar
• 4 Casale R, Polati E, Schweiger V, Coluzzi F, Bhaskar A, Consalvo M. [Localized neuropathic pain – 5% lidocaine medicated patch as a first-line treatment and as add-on therapy: literature review and personal experience]. Minerva Med. 105(3), 177–195 (2014).
  Medline CASGoogle Scholar
• 5 Kraut L, Fauser AA. Anti-emetics for cancer chemotherapy-induced emesis: potential of alternative delivery systems. Drugs 61(11), 1553–1562 (2001).
  Medline CASGoogle Scholar
• 6 Duggan ST, Curran MP. Transdermal granisetron. Drugs 69(18), 2597–2605 (2009).
  Medline CASGoogle Scholar
• 7 Coluzzi F, Rocco A, Mandatori I, Mattia C. Non-analgesic effects of opioids: opioid-induced nausea and vomiting: mechanisms and strategies for their limitation. Curr. Pharm. Des. 18(37), 6043–6052 (2012). • The authors discuss the latest advances in the mechanism of opioid-induced nausea and vomiting, and the mechanism of action of different antiemetic drugs.
  Medline CASGoogle Scholar
• 8 Howell J, Smeets J, Drenth HJ, Gill D. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. J. Oncol. Pharm. Pract. 15(4), 223–231 (2009).
  Medline CASGoogle Scholar
• 9 Haislip ST, Gilmore JW, Howell JD. Results from four pharmacokinetic studies of the granisetron transdermal system. Res. Rep. Transderm. Drug Deliv. 2013(2), 19–26 (2013).
  Google Scholar
• 10 European Medicines Agency. EMA Public Assessment Report Sancuso^® 16 February 2012 EMA/228344/2012. Committee for Medicinal Products for Human Use (CHMP). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002296/WC500127130.pdf.
  Google Scholar
• 11 Tuca A. Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review. Cancer Manag. Res. 2, 1–12 (2010).
  CASGoogle Scholar
• 12 Keating GM, Duggan ST, Curran MP. Transdermal granisetron: a guide to its use in preventing nausea and vomiting induced by chemotherapy. CNS Drugs 26(9), 787–790 (2012).
  Medline CASGoogle Scholar
• 13 Howell J, Clark G, Yellowlees A, Gutierrez-Esteinou R. Efficacy, safety, and tolerability of a transdermal granisetron patch for prevention of single-dose chemotherapy-induced nausea and vomiting: Phase II trial results. J. Oncol. Pharm. Pract. 15(Suppl. 2), 20 (2009).
  Google Scholar
• 14 Straken Pharmeceutical Ltd. Clinical Study Report 392MD/8/C, May 2007.
  Google Scholar
• 15 Aapro M, Fabi A, Nolè F et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann. Oncol. 21(5), 1083–1088 (2010).
  Medline CASGoogle Scholar
• 16 Celio L, Frustaci S, Denaro A et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, Phase III trial. Support Care Cancer 19(8), 1217–1225 (2011).
  MedlineGoogle Scholar
• 17 Komatsu Y, Okita K, Yuki S et al. Open-label, randomized, comparative, Phase III study on effects of reducing steroid use in combination with palonosetron. Cancer Sci. 106(7), 891–895 (2015).
  Medline CASGoogle Scholar
• 18 MASCC/ESMO antiemetic guideline 2016. www.mascc.org/assets/Guidelines-Tools/mascc_antiemetic_guidelines_english_2016_v.1.1.pdf.
  Google Scholar
• 19 Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, Phase III study. Support Care Cancer 19(10), 1609–1617 (2011).
  MedlineGoogle Scholar
• 20 Kim JE, Hong YS, Lee JL et al. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. Support Care Cancer 23(6), 1769–1777 (2015).
  MedlineGoogle Scholar
• 21 Boccia RV, Clark G, Howell JD. Use of transdermal and intravenous granisetron and the ability of the Hesketh score to assess nausea and vomiting induced by multiday chemotherapy. Cancer Manag. Res. 4, 171–176 (2012).
  Medline CASGoogle Scholar
• 22 Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J. Clin. Oncol. 15(1), 103–109 (1997).
  Medline CASGoogle Scholar
• 23 Seol YM, Kim HJ, Choi YJ et al. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and Phase IV study. Support Care Cancer 24(2), 945–952 (2015). •• In this Phase IV study granisetron transdermal delivery system was compared with palonosetron and proved to be a valuable alternative therapeutic option for chemotherapy-induced nausea and vomiting.
  MedlineGoogle Scholar
• 24 Dunnington H, Hunter R, Frumovitz M, Smith J. Granisetron transdermal patch for treatment of nausea in patients undergoing cisplatin based chemotherapy for cervical cancer. J. Cancer Ther. 3, 1159–1163 (2012).
  Google Scholar
• 25 Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M, Williams CJ. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother. Oncol. 68(3), 217–226 (2003).
  MedlineGoogle Scholar
• 26 Coluzzi F, Berti M. Change Pain: changing the approach to chronic pain. Minerva Med. 102(4), 289–307 (2011).
  Medline CASGoogle Scholar
• 27 Brygger L, Herrstedt J. 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects. Expert Opin. Drug Saf. 13(10), 1407–1422 (2014).
  Medline CASGoogle Scholar
• 28 International Conference on Harmonisation (ICH). Guidance for industry: E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073153.pdf.
  Google Scholar
• 29 Mason JW, Moon TE. Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management. Cancer Manag. Res. 5, 179–185 (2013).
  MedlineGoogle Scholar
• 30 Drug safety communication: Abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate). Silver Spring, MD, USA: US FDA (2010). www.fda.gov/Drugs/DrugSafety/ucm237081.htm#safety_announcement.
  Google Scholar
• 31 Sanofi-Aventis. ANZEMET (dolasetron mesylate) – withdrawal of 20 mg/mL intravenous injection due to potential risk of arrhythmias – for health professionals. Health Canada endorsed important safety information on ANZEMET intravenous injection. www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/14633a-eng.php.
  Google Scholar
• 32 Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann. Emerg. Med. 64(1), 19–25.e16 (2014).
  MedlineGoogle Scholar
• 33 Drug safety communication: New information regarding QT prolongation with ondansetron (Zofran) Silver Spring, MD, USA: US FDA, 29 June 2012. www.fda.gov/Drugs/DrugSafety/ucm310190.htm.
  Google Scholar
• 34 Gonullu G, Demircan S, Demirag MK, Erdem D, Yucel I. Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 20(7), 1435–1439 (2012).
  MedlineGoogle Scholar
• 35 Kim HJ, Lee HC, Jung YS et al. Effect of palonosetron on the QTc interval in patients undergoing sevoflurane anaesthesia. Br. J. Anaesth. 112(3), 460–468 (2014).
  Medline CASGoogle Scholar
• 36 Kytril (granisetron hydrochloride) tablets [package insert]. Nutley, NJ, USA: Roche Laboratories Inc. (2010). http://www.drugs.com/pro/kytril.html.
  Google Scholar
• 37 Patel DR, Joshi A, Patel HH, Stagni G. Development and in-vivo evaluation of ondansetron gels for transdermal delivery. Drug Dev. Ind. Pharm. 41(6), 1030–1036 (2015).
  Medline CASGoogle Scholar
• 38 Woodall R, Arnold JJ, Mckay D, Asbill CS. Effect of formulation pH on transdermal penetration of antiemetics formulated in poloxamer lecithin organogel. Int. J. Pharm. Compd. 17(3), 247–253 (2013).
  Medline CASGoogle Scholar
• 39 Kamen C, Tejani MA, Chandwani K et al. Anticipatory nausea and vomiting due to chemotherapy. Eur. J. Pharmacol. 722, 172–179 (2014). • The review is mainly focused on psychological processes and treatment-related factors that are linked with anticipatory nausea and vomiting.
  Medline CASGoogle Scholar
• 40 Simmons K, Parkman HP. Granisetron transdermal system improves refractory nausea and vomiting in gastroparesis. Dig. Dis. Sci. 59(6), 1231–1234 (2014).
  MedlineGoogle Scholar
• 41 Caritis S, Zhao Y, Chen HJ, Venkataramanan R. Pharmacodynamics of transdermal granisetron in women with nausea and vomiting of pregnancy. Am. J. Obstet. Gynecol. doi:10.1016/j.ajog.2016.01.163 (2016) (Epub ahead of print).
  Google Scholar